A peptide certificate of analysis (COA) supports a claim only when that claim is tied to a named method and to the batch that was tested. Identity, chromatographic purity, and peptide content answer different questions. An unlisted test stays unknown: it is not a pass, a fail, or a zero. A purity result does not establish sterility, conformational homogeneity, or suitability for a protocol.
Match identifiers before you read a number
A product name is not a unique record. Site documentation treats a SKU as the listed size and pack variant, a batch number as the material that was tested, and a certificate identifier as the issued report. Those three fields should match the vial in hand. A report for one size is not evidence for another SKU of the same peptide, and an older published batch is not evidence of a later shipment. A missing public result is neither a pass nor a fail (How to find a COA by SKU and batch). The same guidance states that a report for SKU RT5 should not be used as evidence for SKU RT10 merely because both names say Retatrutide.
Nominal vial size and pack quantity are catalog fields, not analytical measurements. A label such as “10 mg × 10 vials” describes ten vials with a nominal 10 mg size each; it is not a single 100 mg vial, and the pack sum is label arithmetic rather than a measured fill. Peptide-content numbers belong only to the particular batch report (Per-vial size versus pack quantity).
Method-to-claim map for identity, purity and content
Read each COA line as a triplet: claim, method, batch. The table is a reading framework, not a requirement that every laboratory run every technique.
| Claim on the COA | Typical method family | What a recorded result can support | What it does not establish |
|---|---|---|---|
| Identity | Mass spectrometry (MS), sometimes with tandem sequencing or related structural work | That the measured mass, and fragments if reported, match the intended sequence or connectivity for that batch | Chromatographic purity, content by mass, or conformational homogeneity |
| Chromatographic purity | Reversed-phase liquid chromatography (RPLC) as the common reference; ion-exchange (IEX) as a complementary impurity view | That, under the stated conditions, the main peak accounts for the reported share of detected species | Sterility, endotoxin status, higher-order structure, or absolute peptide mass |
| Content / assay | A quantitative method reported on the same batch, distinct from area-percent purity | How much peptide was measured in that batch, in the units given | That catalog milligrams per vial were confirmed, or that the material is suitable for a protocol |
RPLC remains the reference technique for peptide purification and analysis, but therapeutic peptides span linear, macrocyclic, and disulfide-rich scaffolds, so one reverse-phase purity trace is an incomplete related-substance picture. In a 23 July 2026 study, Goyon, Wang and Zhang evaluated two strong cation exchangers and two strong anion exchangers (all 2.1 × 50 mm) for impurity profiling of therapeutic peptides. Standard protein IEX methods were unsuitable for the target peptides. Salt-gradient elution at pH 2.0 (cation exchange) and pH 10.0 (anion exchange) outperformed the pH-gradients they tested. Secondary hydrophobic interactions affected performance, and at least 30% acetonitrile was needed to mitigate peak broadening and improve peptide recovery. They then benchmarked the IEX methods against an in-house RPLC purity method in forced-degradation studies and explored IEX retention as a route to peptide pI estimates, noting both potential and current limitations (Ion-exchange chromatography for impurity profiling of therapeutic peptides).
The COA implication is that orthogonal methods answer orthogonal questions. An RPLC area-percent purity does not substitute for an IEX impurity profile, and neither substitutes for a content assay. If only one of those appears on the certificate, the others remain unknown.
Higher-order structure is a separate claim
Sequence identity by mass still leaves room for coexisting conformers. Zhu, Ge, Huang and Xu (17 August 2026) applied cyclic ion mobility–mass spectrometry (cIM-MS) with accelerated thermal stress to a manufacturing batch of ziconotide and linaclotide. Pronounced conformational heterogeneity was observed for both peptides under native conditions. Thermal stress produced degradation and structural reorganization that, the authors report, were not adequately captured by conventional methods. They present cIM-MS as a spatially resolved platform for mapping conformers and stress-induced transitions in constrained peptide frameworks (Resolving conformational polymorphism in disulfide-rich peptide drugs).
Stapled macrocycles raise a related assignment problem. Gong and co-workers (17 June 2026) noted that competing stapling pathways often generate structurally heterogeneous products. Their MS platform used MS-grade proteases for controlled enzymatic linearization under mild conditions, converting rigid cycles into linear surrogates that could be sequenced while retaining staple-dependent connectivity. Combined with ion mobility, the workflow separated and quantitatively monitored regioisomeric stapled products; covalent labeling was used to localize modification sites in constrained mono- and bicyclic systems (Mass Spectrometry-Based Structural Characterization and Reaction Kinetics Profiling of Stapled Peptides through Enzymatic Linearization).
As of literature captured on 5 October 2026, these analytical papers show that identity-by-mass and RPLC purity can leave conformational or regioisomeric heterogeneity unresolved. They do not prescribe a COA template, and they do not make a typical research-peptide certificate equivalent to a therapeutic characterization package. One specific remaining question is whether a given batch’s reported RPLC purity would have distinguished the native-condition conformers that cIM-MS resolved for ziconotide and linaclotide—an answer that cannot be read from a certificate that never ran ion-mobility or another orthogonal structural method.
Close the loop on the document, not the product name
- Confirm product name, SKU, batch number, and certificate identifier refer to the same record.
- For identity, note the method and the determination recorded for that batch.
- For purity, note the chromatographic mode and the reported result; do not treat it as content, sterility, or conformational homogeneity.
- For content, use only a quantitative assay on the same batch report; catalog milligrams per vial are not that assay.
- Treat every unlisted test as unknown.
- Do not transfer results across SKUs, blends, or unpublished later batches.
Site documentation of this kind is editorial guidance for reading listed records. It does not establish sterility, storage performance, or suitability for human or animal use.
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.